Wellbutrin for depression
Biovail also filed suit in the United States District Court For wellbutrin for depression the Southern District of Florida against Abrika Pharmaceuticals LLLP, which has submitted an ANDA for a generic 150mg version of Wellbutrin XL(R). The medicine is also considered approvable by the regulatory agencies of 21 other countries2 under wellbutrin for depression the Decentralized Procedure. And each death is a little island, Grey says. As necessary, the dosage can be increased, up to a maximum of 200 mg per day. Many patients with major depressive disorder have a seasonal pattern to their disease. (NASDAQ NM: IPXL) today announced that Glaxo Wellcome, Inc. , a wholly owned subsidiary of Glaxo Wellcome, plc (NYSE: GLX), has filed a lawsuit against the Company in the Northern District of California alleging patent infringement related to IMPAX’s filing of Abbreviated New Drug Applications (ANDA) for generic versions of Wellbutrin SR(R) (bupropion hydrochloride) Sustained-Release Tablets and Zyban(R) (bupropion hydrochloride) Sustained-Release Tablets. Securities and Exchange Commission ("SEC"), the Ontario Securities Commission ("OSC"), and other Wellbutrin for depression securities regulatory authorities in Canada. We are very confident that our formulation does not infringe the Glaxo Wellcome patent, said Barry R. We expect to reach our objective of filing six new applications in 2003. Wellbutrin for depression impax has twenty ANDAs pending at the FDA, including three tentatively approved, that address more than $6. 4 billion in U. A combined analysis of the trials showed that the drug reduces the chance of developing a seasonal major depressive episode by 44 percent. The new Wellbutrin Once Daily will offer physicians greater prescribing flexibility, the potential for improved patient convenience and compliance as well as a modified drug release profile. Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of wellbutrin for depression pharmaceutical products utilizing advanced drug delivery technologies. "Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995 To the extent any statements made in this press release contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and within the meaning of the "safe harbor" provisions of applicable Canadian securities legislation. Wellbutrin XL(R) is indicated for the treatment of major depressive disorder in patients aged 18 and older. Maine recently proposed legislation for a drug Wellbutrin for depression take-back program similar to those in Europe and Canada. Pharmacokinetics Sertraline is more than 97 percent bound to serum protein in rats and dogs. [2,3] Little information is wellbutrin for depression available on the distribution of this drug in humans. The combined annual sales for Wellbutrin(R) SR and Zyban(R) in Canada are expected to wellbutrin for depression reach over US$30 million in 2002 and are expected to grow significantly over the next five years. IMPAX has submitted its filing with the U.